vom 06.12.2018

NCT/DKTK-MASTER: Cancer genome analysis nearing clinical application

[Translate to Englisch:] Technologien zur Krebsgenomsequenzierung können genetische Veränderungen umfassend und detailliert erfassen.
[Translate to Englisch:] Technologien zur Krebsgenomsequenzierung können genetische Veränderungen umfassend und detailliert erfassen.

Scientists today are able to observe tumor cells in increasing detail and thus gain a better understanding of how cancer cells differ from healthy ones. Doctors and scientists from the National Center for Tumor Diseases (NCT), the Institute of Pathology at Heidelberg University Hospital (UKHD) and the German Cancer Consortium (DKTK) completed a prospective study that systematically verified data on cancer genome analysis. Conducted over a period of three years, the study examined more than 200 patients with tumor diseases that are at an advanced stage or difficult to treat who underwent a cancer genome analysis within the scope of the NCT/DKTK-MASTER program. In the validation study as part of the program, the scientists show how comprehensive cancer genome analysis and evaluation can be optimized in such a way that they can be used for clinical application.

The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD), and German Cancer Aid.


In most cancer diseases, the uncontrolled growth of cells is caused by defects in the genetic material. The pattern of genetic changes may differ from patient to patient or even within a tumor. It is therefore important to understand these patterns in order to gain a better understanding of each individual disease. In addition, certain gene mutations are often the point of attack for targeted therapies. Discovering even the smallest genetic defects within a cell requires precise testing methods that examine both the genetic material for defects as well as the protein molecules in a cell. These precise analysis methods include omics technologies, which are new procedures used to create molecular profiles of cells, tissues, and tumors within a short period of time. The technologies for the cancer genome sequencing play a special role, as they can record genetic changes both comprehensively and in detail.

With the MASTER program (Molecularly Aided Stratification for Tumor Eradication), the NCT Heidelberg along with its partners based in Heidelberg, DKFZ, and UKHD, has created the infrastructures required to make comprehensive cancer genome analysis an integral part of molecular diagnosis in clinical practice. The program has been extended to all seven DKTK partner sites in Germany, also by setting up and networking among the molecular tumor boards. NCT and UKHD offer cancer patients wide-ranging molecular analysis tailored to match the individual clinical situation. Complementary to the specific genome analysis which is available to all oncology patients at the Heidelberg sites who have been given the corresponding clinical diagnosis, the MASTER program strives to identify new tumor treatment approaches adapted to the individual tumor profile for young patients with cancer in advanced stages and patients with rare forms of cancer by applying a wide-ranging cancer genome analysis.

In the present study, researchers analyzed more than 200 cancer patients at all DKTK sites during the period from 2013 to 2016 who underwent comprehensive cancer genome analysis within the scope of the MASTER program. The tests aimed to verify the discovered gene changes by using established methods long since used in cancer diagnosis.

The detailed analyses and control steps enabled the researchers to improve the work procedures and processes for the molecular analysis of cancer patients and increase the reliability of the resulting clinical statements. “We can now say with more certainty that the analysis in the MASTER program are very reliable; at the same time, we also identified and eliminated weaknesses. This applies, in particular, to detecting so-called gene fusions, which often occur in cancer. The results are an important step on the path towards the wide clinical application of molecular analysis,” says Professor Stefan Fröhling, Managing Director of the NCT Heidelberg.

“The MASTER validation study is currently the world’s largest and most systematic of its kind. In North America, there are very few programs that take a similar approach,” comments Professor Albrecht Stenzinger, Director of the Molecular Pathology Center at UKHD. “The comprehensive study would not have been possible without the exemplary interdisciplinary collaboration of doctors, molecular biologists, bioinformaticians, geneticists and pathologists and the cooperation between the various institutions.”

Since 2016, additional patients have undergone molecular analysis in the MASTER program. “We have evaluated the tumor genomes of more than 1,100 patients and adapted the planned therapies based on these results,” Fröhling added.

Point of contact for patients and referring physicians

To register or ask questions about the NCT MASTER program, please send an email to the study office at master@nct-heidelberg.de. Currently, young patients (< 50 years of age) or patients with rare tumors are included in the study.

Original publication:
A. Lier, R. Penzel, C. Heining et al. (2018) Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK MASTER Experience. JCO Precision Oncology. DOI 10.1200/PO.18.00171

An image for the press release is available free of charge on the internet:
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/Meldungen/Bilder/DKFZ_Sequenzer_140818_6606_retusche.jpg
Caption: Technologies for cancer genome sequencing can record genetic changes both comprehensively and in detail.

Notice for image material in press releases

The use of images is free of charge. The NCT Heidelberg permits one-time use in connection with coverage of the subject of the press release. Please list the photo credit as “NCT Heidelberg”. The transmission of photographic material to third parties is only permitted after prior consultation with the NCT Press Office (Tel. 06221 56 5930, Email: friederike.fellenberg@nct-heidelberg.de). Use for commercial purposes is prohibited.

Press contact:
Dr. Friederike Fellenberg
National Center for Tumor Diseases Heidelberg (NCT)
Press and Public Relations
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 56-5930
Fax: +49 6221 56-5350
E-mail: friederike.fellenberg@nct-heidelberg.de
www.nct-heidelberg.de

Dr. Sibylle Kohlstädt
German Cancer Research Center (DKFZ)
Communications and Marketing
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg
Tel.: +49 6221 42-2843
Fax: +49 6221 42-2968
E-mail: s.kohlstaedt@dkfz.de
www.dkfz.de

Doris Rübsam-Brodkorb
Heidelberg University Hospital and Medical Faculty of the University of Heidelberg
Press and Public Relations
Im Neuenheimer Feld 672
69120 Heidelberg
Tel.: +49 6221 56-5052
Fax: +49 6221 56-4544
Email: doris.ruebsam-brodkorb@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de

National Center for Tumor Diseases Heidelberg (NCT)
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT’s goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. In 2015, the NCT Heidelberg established a partner location in Dresden.

Heidelberg University Hospital
Heidelberg University Hospital is one of the most important medical centers in Germany; Heidelberg University’s Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 13,000 individuals and are involved in training and qualification. Every year approximately 65,000 patients are treated as inpatients and 56,000 as day patients in more than 50 specialized clinical departments with around 2,000 beds, with more than 1 million patients being treated as outpatients. Together with the German Cancer Research Center and German Cancer Aid, the Heidelberg University Hospital established The National Center for Tumor Diseases (NCT) Heidelberg as the leading oncology center of excellence in Germany. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present 3,700 aspiring physicians and doctors are studying in Heidelberg.

German Cancer Research Center (DKFZ)

The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.
The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Together with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic.
In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.